ONCOLOGY SUCCESS STORY

Completeing LPLV Ahead of Schedule Despite Complex Enrollment Criteria

PharPoint was selected as a full-service CRO providing project management, clinical monitoring, site management, biostatistical support and data management for a Phase 1 study in metastatic breast cancer.

The study used a modified-Fibonacci dose-escalation 3+3 design, with 15 sites enrolled across 4 US sites.

The study had particiularly complicated enrollment criteria. To facilitate enrollment, PharPoint's clinical lead worked hand-in-hand with the study's Sponsor to perform enrollment adjudication. This study-tailored process was used to assist sites with the enrollment of subjects, ensuring their eligibility to improve data quality and subject safety throughout the study.

Each cohort filled within the expected timeframe. Together, the team for this study was able to complete last patient, last visit ahead of schedule.

AWARDED

PharPoint provides full-service support for a **Phase 1 oncology** study

SUPPORTED

PharPoint supports Sponsor with a **study-tailored** enrollment adjudication process

ENROLLED

15 patients are enrolled across 4 US-based sites

EARLY LPLV

Each cohort filled within the expected timeline and LPLV was **completed ahead of schedule**

Get attentive CRO support for your upcoming oncology study.

Reach out to the PharPoint team at **pharpoint.com/contact/** for more information